Consumer Health Education & Advocacy Training
BlueRipple Health equips you to understand your options for detecting, diagnosing, and treating coronary artery disease — and to advocate for yourself within a system that rewards proactivity.
Portal
The optimal balance between diagnostic accuracy, safety, and cost-effectiveness.
A fundamentally different approach to lowering LDL cholesterol.
The inherited risk factor most doctors never test for.
Banach et al., 2025 · Meta-analysis
Adding ezetimibe to a statin cut cardiovascular events and deaths beyond a statin alone — a combination that is cheap, generic, and underused.
Sehayek et al., 2025 · Systematic review
Across more than 590,000 people, apoB tracked cardiovascular risk more faithfully than LDL-C or non-HDL-C wherever the measures disagreed.
Ryan et al., 2024 · Prespecified analysis of randomized trial
In adults with obesity but not diabetes, semaglutide produced sustained weight loss across four years — without the rebound most diets bring.
A long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.
Read moreResearch Highlights: The risk of being hospitalized or dying from COVID-19 infection was lower among adults with better heart health scores. Adults without cardiovascular disease and with the best levels of heart health, as indexed by the American...
Read moreDALLAS, Dec. 16, 2025 — There is increasing evidence that gum disease is associated with increased risk of cardiovascular events, including heart attack, stroke, atrial fibrillation, heart failure and cardiometabolic health conditions. Effective...
Read moreGet lifetime access to the Portal — a comprehensive, independent analysis of every option available for coronary artery disease.
Get Lifetime Access — $197